Complete Blood Morphology (CBM)
First AI-powered solution to fully automate blood morphology analysis
Software · Cloud SaaSCompany source
Company profile
About Scopio Labs
Scopio Labs is a digital pathology company specializing in hematology and laboratory diagnostics. The company has developed a Full-Field imaging technology platform that revolutionizes how clinical hematology teams analyze peripheral blood smears and bone marrow aspirate samples. Their solution replaces traditional manual microscopy with fully digital workflows, capturing dynamic images at 100x resolution that allow clinicians to view thousands of cells across the entire slide—from monolayer to feathered edge. Scopio's platform includes two imaging devices: the X100 for small to medium labs (processing 15 slides per hour) and the X100HT for high-throughput environments (processing 40 slides per hour). The technology integrates AI-powered decision support for automated cell morphology analysis, including their Complete Blood Morphology (CBM) application that provides fully autonomous analysis from scan to final report. The platform addresses critical challenges in hematology labs including rising workloads, staff shortages, and the need for remote access and collaboration. Clinical studies demonstrate the technology reduces turnaround time for peripheral blood smear reviews by 60% while improving diagnostic accuracy through analysis of significantly more cells than traditional manual differentials. Scopio Labs partners with leading hematology and pathology laboratories globally, including major health systems and reference labs, to standardize morphology results and enable remote expert consultation across hospital networks.
Company description Scopio Labs official website
Primary marketPathology & Laboratory Diagnostics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Scopio Labs?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Autoimmune hemolytic anemia (AIHA)
- Chronic myeloid leukemia (CML)
- Diffuse large B-cell lymphoma (DLBCL)
- General hematology diagnostics
- Malaria
- Multiple myeloma (MM)
- Myelodysplastic syndrome (MDS)
- Plasma cell dysplasias
Who it serves
- Clinical hematology departments
- Hospital hematology laboratories
- Multi-site health systems
- Pathology laboratories
- Reference laboratories
Deployment & integration
Cloud Saas · On Premise deployment with recorded integration context.
Geographic context
MarketsBelgium · Europe · Switzerland · United Kingdom · United States
Company sourceOfficial website
Company milestones
Platform expansion
Development of Complete Blood Morphology (CBM) fully autonomous analysis application. Expansion of FDA clearance and CE marking for peripheral blood smear application. Clinical validation studies published in 2024.
Partnerships
Recorded partners
- Ghent University Hospital
- Global distribution partners (unnamed)
- PathGroup
- Southwest Pathology Services
- SYNLAB pathology partnership
- Zentrum für Labormedizin, Switzerland
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Full-Field Bone Marrow Aspirate Application
Industry-only full-field digital bone marrow imaging and analysis platform
Platform · Cloud SaaSCompany source
Full-Field Peripheral Blood Smear Application
AI-powered digital platform replacing manual microscopy for peripheral blood smear analysis
Platform · Cloud SaaSCompany source
Scopio X100
Full-Field digital imaging platform for small and medium hematology labs
Device · On PremiseCompany source
Scopio X100HT
High-throughput digital imaging platform for large hematology laboratories
Device · On PremiseCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
No linked records are currently available.
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
X100/X100HT with Full Field Peripheral Blood Smear (PBS) ApplicationK243144 · 510k · Jun 27, 2025
X100HT with Slide Loader with Full Field Peripheral Blood Smear (PBS) ApplicationK220013 · 510k · May 3, 2022
X100 with Full Field Peripheral Blood Smear (PBS) ApplicationK201301 · 510k · Oct 2, 2020
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
60% reduction in turnaround time
Peripheral blood smear reviews compared to manual microscopy
Analysis of thousands of cells vs 100 cells
Improved statistical significance compared to manual differential counts
100% digital workflow
Complete replacement of manual microscopy
Ghent University Hospital
High-quality diagnostic imaging with ability to move freely around slides for identifying dysplastic cells, blasts, and plasma cell dysplasias
Enabled identification of areas of abnormal cells including blasts and multiple myeloma through Full-Field imaging at 100x
PathGroup
Improving quality in hematopathology through digitization and AI-powered differential analysis
Improved statistical significance and confidence by analyzing more cells than manual 100-cell differentials, reduced risk of missing rare cell types
Southwest Pathology Services (SYNLAB partnership)
Remote slide sharing and expert consultation across multiple sites for faster diagnosis
Enabled remote malaria detection and speciation across 5+ miles between hospitals, staff quickly stopped using microscopes entirely
Zentrum für Labormedizin
Complete digitization to replace light microscopy and standardize morphology results across the entire health system
Achieved full digitization with image quality as good as looking through a microscope, standardized morphology results across all labs in the system
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Itai Hayut
Co-Founder and CEO
Erez Na'aman
Co-Founder and CTO
Amir Shlomovich
Chief Operations Officer
Yossi Maimon
Chief Financial Officer
Iris Getz
Chief Strategy Officer
Amir Farhi
Chief Commercial Officer
Amy Meitus
Chief Product Officer
Guy Meger
SVP R&D
06 · Company updates
Updates from Scopio Labs
Recent articles published on Scopio Labs's official website.
How AI and Digital Hematopathology Transform Bone Marrow Examination
Read on Scopio LabsDifferential Diagnostic dilemmas: BMA to the rescue
Read on Scopio LabsMDS Unpacked: Diverse Hematology With Dysplasia At The Core
Read on Scopio LabsWhole Slide Imaging Trade-Offs in Hematopathology Diagnostics
Read on Scopio LabsQuality Control in Hematology Laboratories: Best Practices, Challenges, and Solutions
Read on Scopio Labs07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Pathology & Laboratory Diagnostics
Companies applying AI to digital pathology, histopathology slide analysis, laboratory diagnostics, or biomarker discovery. Includes AI-powered interpretation of lab test results, at-home diagnostic devices with AI analysis, and platforms that analyze tissue samples or biological specimens to support clinical diagnosis.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.